Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing covers the month of May 2026, specifically dated May 7, 2026. Haleon Plc is a consumer health company focused on everyday health, with a portfolio spanning Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. The filing serves as a routine annual update regarding the company's debt financing program.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, or liquidity ratios. The primary financial disclosure relates to the company's debt capacity:
- Debt Facility: A £10,000,000,000 (10 billion GBP) Euro Medium Term Note (EMTN) Programme.
- Issuers: Haleon UK Capital plc and Haleon Netherlands Capital B.V.
- Guarantor: Haleon Plc.
Material Changes
The filing announces the publication of updated listing particulars for the EMTN Programme following a routine annual update. No material changes to operational performance or financial results are disclosed in this specific document.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future performance, or specific risk factors beyond standard legal disclaimers. A key contingency noted is that the information in the Listing Particulars is targeted at residents of specific countries and should not be relied upon by persons outside those jurisdictions without verification.
Investor Verification Checklist
- Verify the full text of the Listing Particulars available at www.haleon.com/investors/debt-investors for detailed terms of the EMTN Programme.
- Confirm eligibility to access the Listing Particulars based on country of residence as specified in the document.
- Review the guarantee structure provided by Haleon Plc for the subsidiaries issuing the notes.